Search

everythinglearnresearchcommunity

for

Search:↓

A woman's total hair loss from hepatitis C treatment grew back after stopping the medication.

Prolactin may be important for skin growth and immune function.

A woman with subacute cutaneous lupus erythematosus had widespread skin symptoms triggered by medication and sunlight, which improved with specific treatments.

Mesenchymal stem cells help improve wound healing by reducing inflammation and promoting skin cell growth and movement.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Low serum complement levels in SLE patients don't always match with disease flares; monitoring C3 and C4 is useful, but cell-bound complement products might better indicate disease activity.

Early detection and stopping the drug are key to managing DRESS, and careful monitoring is important due to possible severe reactions.

Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.

People with Major Depressive Disorder have a higher chance of getting Alopecia Areata, and vice versa; antidepressants may lower this risk.

Hair loss requires customized treatments based on its various causes and types.

Early diagnosis and treatment are crucial for preventing permanent hair loss in various scalp conditions, and while new treatments are promising, more research is needed to evaluate their effectiveness.

Bone-marrow and epidermal stem cells help heal wounds differently, with bone-marrow cells aiding in blood vessel formation and epidermal cells in hair growth.

Cells from a skin condition can create new hair follicles and similar growths in mice, and a specific treatment can reduce these effects.

Androgens may influence T cells, contributing to higher autoimmune liver disease risk in women.

Alopecia Areata is a complex, unpredictable autoimmune hair loss condition with limited treatment options and a significant psychological impact.

Pregnancy can change skin disease severity, with some conditions improving and others worsening, and treatment should balance benefits and fetal safety.

Behçet's Disease may be caused by genetic and environmental factors leading to abnormal immune responses, and stress management and new treatments could improve patient outcomes.

Skin problems like itching, dry skin, and hair loss are more common in hepatitis C patients after interferon treatment, but lichen planus is not linked to the infection.

Stress and emotional factors can worsen skin conditions by affecting the immune system.

Systemic Lupus Erythematosus has varied symptoms and is hard to diagnose, affecting many body parts and requiring careful clinical judgment.

Pregnancy can cause specific skin conditions that need correct diagnosis and treatment to protect both mother and baby.

Alefacept showed some effectiveness for alopecia areata but needs more research.

The document concludes that recognizing oral lesions is important for diagnosing syphilis.

APS-1 in Italy shows diverse AIRE mutations and various autoimmune issues.

Psychotropic medications can cause skin reactions, including severe conditions like SJS and TEN, and it's important for psychiatrists to recognize and manage these side effects.

The article concludes that developing in vitro models for human hair structures is important for research and reducing animal testing, but there are challenges like obtaining suitable samples and the models' limitations.

Acne is significantly influenced by genetics, and understanding its genetic basis could lead to better, targeted treatments.

Hair disorders are caused by a complex mix of biology, genetics, hormones, and environmental factors, affecting hair growth and leading to conditions like alopecia.

Cell-based therapies show promise for treating Limbal Stem Cell Deficiency but need more research.

Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.